summari posit growth fundament
like resolv key debat capac util demand
elast bullish direct ahead ilmn like guid
next week rais estim above-consensu level
rais pt upgrad rate
outperform market perform
return versu
sinc day novaseq launch earli may
prompt investor ask whether chase stock
think
import rememb
under-perform market period still
all-tim high think stock strong
perform investor give compani
benefit doubt earli inning product cycl took
option wait clearer pictur given signific
controversi erupt end ilmn last product cycl
think clearer pictur start emerg
controversi may resolv ilmn favor key factor
decis upgrad earli evid controversi
demand elast capac util plagu final
inning hiseq cycl may resolv ilmn favor
novaseq cycl earli evid come dilig well
ilmn statement analysi report data exhibit
also believ could good year certain portion
clinic sequenc market key piec confirmatori data could
guidanc rang novaseq pull-through expect
give sometim look number
rang drive increas util base transit
expect januari expect use sell-sid
confer next week initi revenu growth ep
guidanc sustain multipl think need guid
acceler revenu growth expect
model think ep guidanc need solidli
street particularli factor tax reform
model bp tax rate reduct also use event
make biggest product announc huge novaseq
surpris arent expect earth-shatt
new product side could get modestli posit
announc relat desktop sequenc key collabor
support long-term growth ilmn state total
address market four year stale
longer relev view note offer updat view
well-defin piec smaller
support support long-term dcf
company-upd could also interest catalyst
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud amort acquir intang asset one-tim restructur
quarter sum due chang ownership grail year
compani prioriti stock list
compani data secur llc estim reuter
may resolv relat controversi ilmn favor
high throughput sequenc revenu weaker expect concern
relat instrument sale biggest issu view hiseq consum sale
weak standard hiseq consum weak creat
major question high throughput sequenc capac alreadi said
admittedli rough calcul even lower impli util room rise
sequenc demand increas look like capac util stall mayb actual
fall earli
environ novaseq launch earli novaseq offer major capac increas
math everi exist hiseq immedi replac novaseq run chip market
capac would increas nine-fold novaseq clearli major technolog step forward
came earlier almost everyon expect sinc hiseq capac util
underwhelm immedi obviou us demand novaseq would play
essenti would market demand lot new capac
avail much new capac also rais question market elast novaseq offer
bring cost mani type studi amount cost reduct depend type
studi chip type ilmn price model base comparison exampl whole human
genom could reduc compar hiseq use chip ilmn initi price
impli pathway bring whole human genom sequenc type
studi inaccess hiseq could see larger initi cost reduct question whether
cost reduct enough open new market drive faster growth exist
market essenti degre market elast question frame
context capac util market prove suffici elast drive
increas capac util across instal base
exhibit show seen past coupl quarter expect see futur
inde think need accomplish justifi valuat upon novaseq launch
capac avail market grew rapidli importantli capac util
held calcul capac util actual tick higher
go think place well novaseq end
identifi institut purchas made purchas public
attest one-third new high-throughput sequenc appear credibl even
cursori glanc known list includ appendix us statist bode well
elast question custom clearli buy new capac check also turn
posit commentari pertain elast particularli outsid visibl whole human
 capac terabaseshiseq consum revenu theoret high throughput annual capac interabaseshigh throughput consum revenu /theoret compani data secur llc estim light red project inc
genome/exom applic exampl research area might elast includ transcriptom
rna-seq microbiom model capac increas continu moder
rate hiseq capac drop time novaseq purchas moder also import
rememb firm control price virtu market domin therefor
like control demand growth somewhat adjust price lever
think import capac util held well initi transit novaseq new
instrument util usual low immedi instal hiseq util held
off-set good sign also import think novaseq resolv ineffici
market hiseq artifici limit softwar certain applic forc buyer
purchas least five instrument optim ten instrument get best price two
limit like help capac util consider good enough us project
util increas overal transit novaseq matur know model
novaseq consum pull-through settl million year end expect
guid rang number sometim think million number would drive
higher util instrument base transit estim theoret maximum pull-through
novaseq run would million per year million would repres averag novaseq
util somewher hiseq somewher rest hiseq instal base
final late offer potenti catalyt data point first fda approv agre
reimburs sever sequenc panel use companion diagnost second prevail
sever lawsuit nipt arena momentum continu build toward widespread accept
clinic area investor may awar gener take cautiou stanc
pace clinic adopt reimburs inde area get traction bullish
part investor these back earli view look us like
year sever market area simultan posit catalyst remain cautiou
challeng clinic market overal could good year sequenc applic
specif technolog continu featur promin mani diagnost compani
expect januari
expect use sell-sid confer next week give initi revenu growth ep guidanc
sustain multipl think need guid acceler revenu growth
expect model think ep guidanc need solidli
street particularli factor tax reform give bp tax
reduct equat thu sourc above-consensu estim
primarili tax smaller upsid estim revenu margin weve discuss revenu
controversi margin model bp margin expans exclud
grail helix seem reason us novaseq product cycl matur
admittedli guid impact tax reform step limb base
analysi non-control interest line also variabl difficult predict howev
guid above-consensu revenu ep impli above-consensu margin think guidanc would
posit catalyst stock
also typic use januari sell-sid event make biggest product announc
huge novaseq surpris arent expect earth-shatt new product side
possibl order most-to-least like might updat desktop strategi
includ detail firefli collabor initi growth market akin grail
helix announc announc nanopor sequenc
justifi ilmn valuat
justifi put price target repres forward earn use long-term
dcf think dcf requir least year revenu growth would put ilmn
revenu neighborhood billion
reason assum reach billion revenu ten year paramet
creat novaseq name price sequenc probabl go fall let think
sever part ilmn
life scienc research put life scienc research billion look
slightli differ think billion life scienc research revenu one
way think elast market would simpli assum research budget grow
certain rate assum low-singl digit global research simpli buy much
sequenc alloc budget assum sequenc take wallet share
within overal research budget appli growth rate research get us tam
billion command share market see noth horizon
alter right
reproduct gave billion reproduct health half
non-invasive prenat test think tam like billion factor
inclus averag risk pregnanc also factor price reduct like novaseq
think continu domin market sinc high-throughput critic also
success solidifi intellectu properti posit
cancer screen launch grail design facilit blood test screen
cancer time gave market size billion high risk patient howev would
grail revenu revenu assum receiv fraction cog
test sinc grail custom think ilmn realist market billion
probabl riskiest assumpt us remain bit skeptic viabil screen
test think dcf demand success market howev market
develop think domin sinc demand high throughput sequenc
exist market think exist market amount billion includ
germlin sequenc consum sequenc forens transplant type companion diagnost
might object companion diagnost alon billion ilmn prior howev
think reduc time assum would purveyor test
instead custom foundat medicin fmi like provid test think ilmn
panel doesnt much traction mean get fraction cog
exist market area competitor like carv posit
new market difficult part think new market might develop exampl
blue-ski type think might use dna inform storag yet practic
sometim discuss think would major player come fruition point
still room expand
summari identifi billion exist market
think domin power billion top new market could develop within
come decad short project billion revenu decad unrealist
also conserv think two key assumpt success cancer screen test
ilmn abil retain domin high-throughput market next decad
institut companylocationdateknown machinesalli global genom research facil colleg medicin institut genom molecular diagnosticscanadanacent genom transcriptom cegat zuckerberg univers institut genom medicin ireland medic genom cancer research integr genom network clinic labusanamed colleg leukemia york genom biousananovogen /cloudhealth state human genet children centr unsw genom research institut san univers servic medic center utrecht umcu netherlandsnaunivers minnesota genom center genom analysi yale-new press releas compani data secur llc life scienc tool servic diagnost
summari data fy end decemb million except per gross research sell gener oper interest expens pre-tax provis incom net incom non-controlling interests- net non-gaap dilut share gross gener net share estim actual hiseq hiseq novaseq instal base estimate actual hiseq hiseq revenu estimateshiseq hiseq novaseq nextseq miseq/miniseq sequenc hiseq hiseq /novaseq nextseq miseq/miniseq sequenc sequenc microarray total growth rateshigh-throughput seq servic servic freight consolid growth total net cash debt ttm flow capit free cash compani file secur llc estimatesmargin analysisrevenu analysisincom statementchang analysi y/i inc
price target
price target dcf-base wacc termin noplat growth impli
slow clinic adopt lack elast research market competit
believ novaseq drive penetr exist market open new market
expect capac util across high throughput instal base begin trend higher
san diego california-bas inc develop manufactur market
life scienc tool use genom compani technolog encompass two major type system
microarray next gener sequenc via novaseq hiseq nextseq miseq miniseq
platform half compani revenu come consum use variou
platform follow instrument system servic outsourc sequenc genotyp
servic well servic contract product custom includ genom research center
compani agrigenom compani consum genom compani
